iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011. In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $200million of proceeds. This additional capital will allow us to continue to develop our clinical pipeline and expand our preclinical pipeline by investing in our discovery research team.
Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, also designed to engage the Fc gamma receptor, or FcγR,. An open-label Phase 1/2a clinical trial of EOS-448 is currently ongoing in adult patients with advanced solid tumors. The company also continues to expand its pipeline through internal research efforts and external collaboration with leading scientists.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics is currently looking for a for a highly motivated, creative and skilled Research Scientist to reinforce its translational medicine team.
As part of the wider translational medicine team, the successful candidate will play a key role in the evaluation of the mechanisms of action of our immune oncology drugs in clinical development and support the selection of biomarkers. In this role, the candidate will work independently and as part of a team to generate robust in vitro data on the products under clinical development, helping to interpret data obtained in clinical trials and refining our biomarker strategy. This is an exciting opportunity for a talented scientist eager to contribute in a meaningful way to the clinical development of innovative IO drugs for cancer patients.
Send your CV together with an adapted cover letter to the following address: email@example.com. Please, mention the reference RS-TM-IO in the mail object. Your application and related information will remain strictly confidential.
For our recruitments in Belgium, we closely collaborate with a Recruitment & Selection company, PaHRtners. Your application will be automatically forwarded to them. We, together with PaHRtners, will keep all your data confidential (GDPR compliant approach ).